Second- and third-generation anticonvulsants have a lower risk of drug-induced liver injury compared to phenobarbital, phenytoin, and carbamazepine

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.